Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Olin

Zynex Inc

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Southwest Airlines

Brunswick

Huntington Bancshares

L3Harris

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Southwest Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Universal Display

Wingstop

Nasdaq-listed stocks have sustained a prolonged rally in recent months, reflecting investor optimism and robust market sentiment. However, in recent days, we have seen a notable pullback in several overvalued stocks, with investors increasingly favoring value over high flyers.

Get Your Money Out of These 3 Nasdaq Stocks by the End of July

Dexcom's shares sank about 38% in premarket trading on Friday after the medical device maker cut its annual revenue forecast, with analysts calling some of the issues 'self inflicted' rather than a broader market growth problem.

Dexcom plunges 40% after glucose monitor maker slashes sales forecast

DexCom reported disappointing earnings, missing estimates by 4% and lowering full-year growth expectations by ~$200 million. Sales in the U.S. market slowed, while international markets saw anemic growth, impacting the company's outlook. Markets blamed sales on poor sales execution, complicated by inefficient distribution channels. Despite strong earnings, DXCM faces challenges with distribution channels and growing competition, leading to a downgrade to Hold.

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Shares in Dexcom (DXCM) lost more than a third of their value in extended trading Thursday after the medical devices company posted second-quarter results that came in below Wall Street expectations and slashed its annual revenue forecast.

Watch These Dexcom Price Levels as Stock Plunges After Guidance Slashed

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) investors concerning the Company's possible violations of federal securities laws. On July 25, 2024, after the market closed, DexCom announced its second quarter 2024 financial results, including $1.004 billion revenue, in a press release stating the Company's “execution did not meet [its] high standards.” The Company also lowered its fu.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DexCom, Inc. (DXCM) on Behalf of Investors

DexCom, Inc. (NASDAQ:DXCM ) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET Corporate Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Magaret Andrew - William Blair Travis Steed - Bank of America Matt Taylor - Jefferies Danielle Antalffy - UBS Joanne Wuensch - Citibank Matthew O'Brien - Piper Sandler Sam Eiber - BTIG Mathew Blackman - Stifel Jason Bedford - Raymond James Steve Lichtman - Oppenheimer Mike Polark - Wolfe Research Shagun Singh - RBC Capital Markets Bill Plovanic - Canaccord Genuity Chris Pasquale - Nephron Matt Miksic - Barclays Operator Welcome to the Dexcom Second Quarter 2024 Earnings Release Conference Call. My name is Abby and I'll be your operator for today's call.

DexCom, Inc. (DXCM) Q2 2024 Earnings Call Transcript

DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago.

DexCom (DXCM) Q2 Earnings Surpass Estimates

Shares of Dexcom (DXCM) tumbled over 40% in extended trading Thursday after the company reported second-quarter earnings that missed estimates and slashed its full-year revenue guidance.

Dexcom Stock Plummets on Earnings Miss, Guidance Cut

Dexcom stock plummeted late Thursday after the diabetes devices maker reported light June-quarter sales and slashed its outlook.

Dexcom Stock Collapses 33% After Sales Miss Leads To $25 Million Guidance Cut

Dexcom shares plummet 30% after company lowers fiscal year guidance

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program.

Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings

Alcon Inc. - Registered Shares

Hologic

Intuitive Surgical

Thermo Fisher Scientific

DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.

The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why DexCom (DXCM) is a Strong Growth Stock

We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.

Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H

Teladoc

Investors are showing varying degrees of appetite for the telehealth and diabetes care industries. Teladoc has undergone major changes in recent years, and investors are warily eyeing its path forward.

2 Healthcare Stocks to Buy at a Discount

CVS Health

HCA Healthcare

UnitedHealth Group

The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging population, technological advances, and rising healthcare costs provide the sector with a compelling combination of growth potential and resilience.

Top 4 Must-Have Healthcare Stocks for Long-Term Growth

Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.

DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs

Shopify

E-commerce powerhouse Shopify has a solid moat and plenty of room to run. DexCom's massive addressable market bodes well for its long-term prospects.

2 Top Growth Stocks to Buy With $1,000

DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing on OTC CGM products like Stelo to expand target market and drive sales. Despite slight downgrade in outlook for FY24, DexCom's stock positioned for robust sales ramp in second half of the year, with potential for +20% upside.

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.

MercadoLibre

Meituan

ServiceNow

Safran SA

Trade Desk

Workday

If you are looking for millionaire-maker stocks to turn a $50,000 portfolio into $1 million in just a decade, I would like to remind you of several things. First, your portfolio would need to compound at around 35% annually.

Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034

DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.

News for DexCom Stock (DXCM)